Detalhe da pesquisa
1.
Genomics to select treatment for patients with metastatic breast cancer.
Nature
; 610(7931): 343-348, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36071165
2.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Breast Cancer Res Treat
; 204(2): 237-248, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38112922
3.
Mutational landscape of inflammatory breast cancer.
J Transl Med
; 22(1): 374, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38637846
4.
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Int J Cancer
; 152(5): 921-931, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36161271
5.
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.
Ann Surg
; 277(1): e153-e161, 2023 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33534229
6.
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Oncologist
; 28(10): e867-e876, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589218
7.
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Breast Cancer Res Treat
; 199(2): 371-379, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36988749
8.
Prevention of aromatase inhibitor-induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer.
Osteoporos Int
; 34(4): 703-711, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36715715
9.
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 191(1): 191-207, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34687411
10.
Immunotherapy and breast cancer: an overview.
Curr Opin Oncol
; 34(5): 587-594, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35838204
11.
Post-traumatic growth 5 years after cancer: identification of associated actionable factors.
Support Care Cancer
; 30(10): 8261-8270, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35821449
12.
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(4): 499-511, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676601
13.
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Breast Cancer Res
; 23(1): 8, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33451345
14.
Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort.
Int J Cancer
; 148(2): 375-384, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32683691
15.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med
; 379(8): 753-763, 2018 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30110579
16.
Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature.
Cancer
; 126 Suppl 16: 3837-3846, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32710666
17.
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET).
Angiogenesis
; 23(2): 193-202, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31773439
18.
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Oncologist
; 25(3): e439-e450, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162822
19.
Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
Curr Opin Oncol
; 32(6): 585-593, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32852311
20.
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Int J Cancer
; 145(12): 3359-3369, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31087564